Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
9 pending office actions • 5 art units • 8 examiners • 0 of 9 (0%) have an AI response strategy ready • 9 patents granted in the last 365 days
Element Biosciences Inc. shows activity in the Biotechnology & Pharmaceuticals technology area with 9 pending office actions. These matters are spread across 5 distinct art units, indicating a range of technical examination for the company's innovations. This diversity of 5 distinct art units suggests that the portfolio covers multiple sub-disciplines within the life sciences sector. Such a broad distribution can lead to varied prosecution timelines depending on the specific art unit workloads.
The company's prosecution involves 8 distinct examiners. HUTSON, RICHARD G is the busiest examiner for the portfolio, managing 2 busiest examiner pending actions. While HUTSON, RICHARD G has the highest individual workload, the remaining 9 pending office actions are distributed among the other 8 distinct examiners. This distribution indicates that the active matters are not concentrated under a single official. Practitioners should prepare for diverse examination styles given that 8 distinct examiners are currently reviewing the company's biotechnology and pharmaceutical claims.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (22%) |
| §102 only | 1 (11%) |
| §112 only | 1 (11%) |
| Double-patenting only | 1 (11%) |
| Double-patenting + other | 2 (22%) |
| Multi-statute (no §101) | 2 (22%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HUTSON, RICHARD G | 2 | 65.1% | +53.1% |
| HSIEH, PING Y | 1 | 79.1% | +15.4% |
| COUSO, JOSE L | 1 | 90.1% | +8.4% |
| BOOSALIS, FANI POLYZOS | 1 | 90.3% | +10.8% |
| KENNEDY, SARAH JANE | 1 | 0.0% | +0.0% |
| BUNKER, AMY M | 1 | 29.1% | +45.5% |
| CHUNDURU, SURYAPRABHA | 1 | 53.3% | +17.8% |
| LU, FRANK WEI MIN | 1 | 62.7% | +67.7% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18959114 | PHASING AND PREPHASING CORRECTION OF BASE CALLING IN NEXT GENERATION SEQUENCING | COUSO, JOSE L | — |
| 18917561 | HIGH PERFORMANCE FLUORESCENCE IMAGING MODULE FOR GENOMIC TESTING ASSAY | BOOSALIS, FANI POLYZOS | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18426101 | NUCLEIC ACID HYBRIDIZATION METHODS | KENNEDY, SARAH JANE | — |
| 18328650 | COMPOSITIONS AND METHODS FOR REDUCING BASE CALL ERRORS BY REMOVING DEAMINATED NUCLEOTIDES FROM A NUCLEIC ACID LIBRARY | BUNKER, AMY M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17705011 | ENGINEERED POLYMERASES | HUTSON, RICHARD G | 99d overdue |
| 17511046 | MULTIVALENT BINDING COMPOSITION FOR NUCLEIC ACID ANALYSIS | CHUNDURU, SURYAPRABHA | 4d overdue |
| 18968535 | IMAGE REGISTRATION IN PRIMARY ANALYSIS | HSIEH, PING Y | — |
| 18917561 | HIGH PERFORMANCE FLUORESCENCE IMAGING MODULE FOR GENOMIC TESTING ASSAY | BOOSALIS, FANI POLYZOS | — |
| 18571678 | Engineered Polymerases | HUTSON, RICHARD G | — |
| 18328650 | COMPOSITIONS AND METHODS FOR REDUCING BASE CALL ERRORS BY REMOVING DEAMINATED NUCLEOTIDES FROM A NUCLEIC ACID LIBRARY | BUNKER, AMY M | — |
| 17245670 | MULTIVALENT BINDING COMPOSITION FOR NUCLEIC ACID ANALYSIS | LU, FRANK WEI MIN | — |
| Art Unit | Apps |
|---|---|
| 1652 | 2 |
| 2668 | 1 |
| 1684 | 1 |
| 1681 | 1 |
| 1683 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18968535 | IMAGE REGISTRATION IN PRIMARY ANALYSIS | HSIEH, PING Y | — | §103 | Non-Final OA | — | Pending | Dec 04, 2024 |
| 18959114 | PHASING AND PREPHASING CORRECTION OF BASE CALLING IN NEXT GENERATION SEQUENCING | COUSO, JOSE L | 2668 | §102Other | Non-Final OA | — | Pending | Nov 25, 2024 |
| 18917561 | HIGH PERFORMANCE FLUORESCENCE IMAGING MODULE FOR GENOMIC TESTING ASSAY | BOOSALIS, FANI POLYZOS | — | §103 | Non-Final OA | — | Pending | Oct 16, 2024 |
| 18426101 | NUCLEIC ACID HYBRIDIZATION METHODS | KENNEDY, SARAH JANE | — | §102§103§112 | Non-Final OA | — | Pending | Jan 29, 2024 |
| 18571678 | Engineered Polymerases | HUTSON, RICHARD G | 1652 | §103§112DP | Non-Final OA | — | Pending | Dec 18, 2023 |
| 18328650 | COMPOSITIONS AND METHODS FOR REDUCING BASE CALL ERRORS BY REMOVING DEAMINATED NUCLEOTIDES FROM A NUCLEIC ACID LIBRARY | BUNKER, AMY M | 1684 | §102§103§112 | Non-Final OA | — | Pending | Jun 02, 2023 |
| 17705011 | ENGINEERED POLYMERASES | HUTSON, RICHARD G | 1652 | §112DP | Final Rejection | 99d overdue | Pending | Mar 25, 2022 |
| 17511046 | MULTIVALENT BINDING COMPOSITION FOR NUCLEIC ACID ANALYSIS | CHUNDURU, SURYAPRABHA | 1681 | DP | Final Rejection | 4d overdue | Pending | Oct 26, 2021 |
| 17245670 | MULTIVALENT BINDING COMPOSITION FOR NUCLEIC ACID ANALYSIS | LU, FRANK WEI MIN | 1683 | §112 | Non-Final OA | — | Pending | Apr 30, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial